Roche stacks up Tecentriq nods, following up breast cancer approval with small cell lung cancer
Roche is carving itself a tidy niche with Tecentriq in cancer pockets that other immunotherapies haven’t yet conquered. After scoring approval in frontline use for breast cancer last week, the Swiss drugmaker on Tuesday said the checkpoint inhibitor has secured the FDA nod as a first-line treatment for extensive-stage small cell lung cancer (ES-SCLC).
Tecentriq will be added to chemotherapy — carboplatin and etoposide — as the first new option in more than two decades for treatment-naive patients whose small cell lung cancer has spread, Roche said, adding that the monoclonal antibody is the only cancer immunotherapy to win approval in this difficult-to-treat category of patients.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.